DHC Stock Analysis: Diversified Healthcare Trust | NASDAQ
REIT - Healthcare Facilities | NASDAQ, USA | Market Cap: 1.816m USD | 12M Return: 86.3% | US25525P1075 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 16.3M
Qual. Beats: 0
Rev. Trend: 87.5%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Diversified Healthcare Trust (NASDAQ: DHC) is a Maryland-incorporated real estate investment trust (REIT) founded in 1998 and headquartered in Newton, Massachusetts. The company focuses on owning healthcare-related real estate across the United States, with a portfolio anchored by senior housing, medical office, and life science properties. As of June 30, 2026, its approximately $6.3 billion portfolio comprised 285 properties in 33 states and Washington, D.C., including 23,797 senior living units, around 5.6 million square feet of medical office and life science space, and roughly 250 tenants. DHC is externally managed by The RMR Group, a U.S. alternative asset manager with over $37 billion in assets under management and 40 years of commercial real estate experience. The trust trades on NASDAQ as a small-cap stock with a market capitalization of roughly $1.97 billion and is classified within the Health Care REITs sub-industry of the Real Estate sector.
As a healthcare REIT, DHC generates revenue primarily through long-term lease agreements and operating partnerships with senior housing operators, hospitals, medical practices, and life science tenants. The senior housing segment typically involves a mix of triple-net leases and managed/operated communities, which can produce more variable operating income but also greater upside compared to the more stable, passively leased medical office and life science components.
- Senior housing occupancy recovery accelerates rental income growth
- Medical office leasing demand offsets portfolio softness
- High debt load pressures refinancing costs and dividends
| Net Income: -266.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA -4.15 > 1.0 |
| NWC/Revenue: 7.74% < 20% (prev 7.41%; Δ 0.34% < -1%) |
| CFO/TA -0.01 > 3% & CFO -22.7m > Net Income -266.0m |
| Net Debt (2.43b) to EBITDA (203.3m): 11.95 < 3 |
| Current Ratio: 189.0 > 1.5 & < 3 |
| Outstanding Shares: last quarter (240.7m) vs 12m ago 0.26% < -2% |
| Gross Margin: -5.25% > 18% (prev 17.76%; Δ -23.01% > 0.5%) |
| Asset Turnover: 33.35% > 50% (prev 32.02%; Δ 1.34% > 0%) |
| Interest Coverage Ratio: -0.23 > 6 (EBIT TTM -49.6m / Interest Expense TTM 218.7m) |
| A: 0.03 (Total Current Assets 116.8m - Total Current Liabilities 618k) / Total Assets 4.24b |
| B: -0.72 (Retained Earnings -3.04b / Total Assets 4.24b) |
| C: -0.01 (EBIT TTM -49.6m / Avg Total Assets 4.50b) |
| D: 0.60 (Book Value of Equity 1.58b / Total Liabilities 2.66b) |
| Altman-Z'' = -1.61 = D |
As of October 17, 2026, the stock is trading at USD 7.59 with a total of 1,202,903 shares traded. Over the past week, the price has changed by +1.20%, over one month by -4.41%, over three months by -17.59% and over the past year by +86.34%.
Current recommended Stop Loss: 7.30 (which is 3.8% or 1.2 ATR below the current price).
Diversified Healthcare Trust has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy DHC.
- StrongBuy: 2
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 10.2 | 33.7% |
P/E Forward = 16.6389
P/S = 1.2105
P/B = 1.2498
P/EG = 1.8917
Revenue TTM = 1.50b USD
EBIT TTM = -49.6m USD
EBITDA TTM = 203.3m USD
Long Term Debt = 2.40b USD (from longTermDebt, last quarter)
Short Term Debt = 618k USD (from shortTermDebt, last quarter)
Debt = 2.55b USD (from shortLongTermDebtTotal, last quarter) + Leases 127.8m
Net Debt = 2.43b USD (calculated: Debt 2.55b - CCE 116.8m)
Enterprise Value = 4.24b USD (1.82b + Debt 2.55b - CCE 116.8m)
Interest Coverage Ratio = -0.23 (Ebit TTM -49.6m / Interest Expense TTM 218.7m)
EV/FCF = -43.95x (Enterprise Value 4.24b / FCF TTM -96.6m)
FCF Yield = -2.28% (FCF TTM -96.6m / Enterprise Value 4.24b)
FCF Margin = -6.44% (FCF TTM -96.6m / Revenue TTM 1.50b)
Net Margin = -17.73% (Net Income TTM -266.0m / Revenue TTM 1.50b)
Gross Margin = -5.25% ((Revenue TTM 1.50b - Cost of Revenue TTM 1.58b) / Revenue TTM)
Gross Margin QoQ = -11.12% (prev -13.62%)
Tobins Q-Ratio = 1.00 (Enterprise Value 4.24b / Total Assets 4.24b)
Interest Expense / Debt = 8.59% (Interest Expense 218.7m / Debt 2.55b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -39.2m (EBIT -49.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 189.0 (out of range, set to none) (Total Current Assets 116.8m / Total Current Liabilities 618k)
Debt / Equity = 1.61 (Debt 2.55b / totalStockholderEquity, last quarter 1.58b)
Debt / EBITDA = 11.95 (Net Debt 2.43b / EBITDA 203.3m)
Debt / FCF = -25.15 (negative FCF - burning cash) (Net Debt 2.43b / FCF TTM -96.6m)
Total Stockholder Equity = 1.64b (last 4 quarters mean from totalStockholderEquity)
RoA = -5.91% (Net Income -266.0m / Total Assets 4.24b)
RoE = -16.22% (Net Income TTM -266.0m / Total Stockholder Equity 1.64b)
RoCE = -1.23% (EBIT -49.6m / Capital Employed (Equity 1.64b + L.T.Debt 2.40b))
RoIC = -0.94% (negative operating profit) (NOPAT -39.2m / Invested Capital 4.16b)
WACC = 6.99% (E(1.82b)/V(4.36b) * Re(7.27%) + D(2.55b)/V(4.36b) * Rd(8.59%) * (1-Tc(0.21)))
Discount Rate = 7.27% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.05 | Cagr: 0.29%
[DCF] Fair Price = unknown (Cash Flow -96.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.26 | # QB: 0
Revenue Correlation: 87.53 | Revenue CAGR: 3.38% | SUE: -0.63 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.13 | Chg30d=+13.33% | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.63 | Chg30d=-5.00% | Revisions=+0% | GrowthEPS=+47.1% | GrowthRev=-4.2%
EPS next Year (2027-12-31): EPS=-0.43 | Chg30d=+8.42% | Revisions=+0% | GrowthEPS=+19.1% | GrowthRev=+6.0%
[Analyst] Revisions Ratio: +12% (up=3, down=2)